CLINICAL TRIALS PROFILE FOR COMBIVIR

All Clinical Trials for COMBIVIR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000887 ↗	A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 1	1969-12-31	The purpose of this study is to see if giving nelfinavir (NFV) plus zidovudine (ZDV) plus lamivudine (3TC) to HIV-positive pregnant women and their babies is safe. This study will also look at how long these drugs stay in the blood. ZDV has been given to mothers in the past to reduce the chances of passing HIV on to their babies. However, better treatments are needed to further reduce these chances and to better suit the treatment needs of mothers and their children. Taking a combination of anti-HIV drugs during pregnancy may be an answer.
NCT00000887 ↗	A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	1969-12-31	The purpose of this study is to see if giving nelfinavir (NFV) plus zidovudine (ZDV) plus lamivudine (3TC) to HIV-positive pregnant women and their babies is safe. This study will also look at how long these drugs stay in the blood. ZDV has been given to mothers in the past to reduce the chances of passing HIV on to their babies. However, better treatments are needed to further reduce these chances and to better suit the treatment needs of mothers and their children. Taking a combination of anti-HIV drugs during pregnancy may be an answer.
NCT00000888 ↗	Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 1	1969-12-31	The purpose of this study is to see if it is safe and effective to give ritonavir (RTV) plus lamivudine (3TC) plus zidovudine (ZDV) to HIV-infected pregnant women during pregnancy and to their babies after birth. Pregnant women who are HIV-positive are at risk of giving HIV to their babies during pregnancy or delivery. It is important to learn how to prevent HIV-positive pregnant women from giving HIV to their babies. RTV and ZDV have been shown to be safe and effective against HIV in adults. The combination of 3 anti-HIV drugs (RTV, 3TC, and ZDV) may help prevent HIV infection from mother to infant but studies are needed to determine whether they are safe and effective during pregnancy.
NCT00000888 ↗	Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	1969-12-31	The purpose of this study is to see if it is safe and effective to give ritonavir (RTV) plus lamivudine (3TC) plus zidovudine (ZDV) to HIV-infected pregnant women during pregnancy and to their babies after birth. Pregnant women who are HIV-positive are at risk of giving HIV to their babies during pregnancy or delivery. It is important to learn how to prevent HIV-positive pregnant women from giving HIV to their babies. RTV and ZDV have been shown to be safe and effective against HIV in adults. The combination of 3 anti-HIV drugs (RTV, 3TC, and ZDV) may help prevent HIV infection from mother to infant but studies are needed to determine whether they are safe and effective during pregnancy.
NCT00000920 ↗	Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 1	1969-12-31	The purpose of this study is to see if it is safe to give saquinavir-SGC (SQV) combined with low-dose ritonavir (RTV) plus zidovudine (ZDV) and lamivudine (3TC) to HIV-positive pregnant women and to see if it is safe to give 3TC and ZDV to their newborns. Another purpose is to see what levels of SQV, low-dose RTV, ZDV, and 3TC are found in mothers and what levels of ZDV and 3TC are seen in newborns. Another purpose of this study is to see whether SQV passes from mother to newborn and if it passes at a level that is safe for the newborn. Although ZDV has been able to reduce the rate of transmission of HIV from mother to child, it may be possible to reduce it further by using a combination of anti-HIV drugs. This study adds SQV (a protease inhibitor [PI]) with RTV (another PI) and 3TC (a reverse transcriptase inhibitor) to the mother's ZDV regimen.
NCT00000920 ↗	Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	1969-12-31	The purpose of this study is to see if it is safe to give saquinavir-SGC (SQV) combined with low-dose ritonavir (RTV) plus zidovudine (ZDV) and lamivudine (3TC) to HIV-positive pregnant women and to see if it is safe to give 3TC and ZDV to their newborns. Another purpose is to see what levels of SQV, low-dose RTV, ZDV, and 3TC are found in mothers and what levels of ZDV and 3TC are seen in newborns. Another purpose of this study is to see whether SQV passes from mother to newborn and if it passes at a level that is safe for the newborn. Although ZDV has been able to reduce the rate of transmission of HIV from mother to child, it may be possible to reduce it further by using a combination of anti-HIV drugs. This study adds SQV (a protease inhibitor [PI]) with RTV (another PI) and 3TC (a reverse transcriptase inhibitor) to the mother's ZDV regimen.
NCT00000944 ↗	A Study to Evaluate the Safety and Tolerance of Combination Anti-HIV Drug Therapy (Indinavir, Lamivudine, and Zidovudine) in HIV-Positive Pregnant Women and Their Infants	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 1	1969-12-31	The purpose of this study is to determine if a combination anti-HIV drug treatment regimen of indinavir plus lamivudine (3TC) plus zidovudine (ZDV) is effective in treating HIV and in reducing the chances of passing HIV from mother to child. This study will also examine if this combination is well tolerated by HIV-positive pregnant women and if a combination of 3TC plus ZDV is safe for newborns. Previous studies in adults and children have shown that indinavir plus 3TC plus ZDV can reduce the amount of HIV in the blood. Most HIV-positive pregnant women usually take ZDV to treat HIV and to reduce the chances of giving HIV to their babies. The combination of drugs in this study may be more effective than ZDV alone.

Clinical Trial Conditions for COMBIVIR

Condition Name

Condition Name for COMBIVIR
Intervention	Trials
HIV Infections	42
HIV Infection	8
HIV	5
Pregnancy	5

Condition MeSH

Condition MeSH for COMBIVIR
Intervention	Trials
HIV Infections	53
Acquired Immunodeficiency Syndrome	12
Infections	10
Infection	7

Clinical Trial Locations for COMBIVIR

Trials by Country

Trials by Country for COMBIVIR
Location	Trials
United States	277
Spain	23
Canada	18
United Kingdom	11
South Africa	10

Trials by US State

Trials by US State for COMBIVIR
Location	Trials
California	29
Florida	20
New York	17
Pennsylvania	16
Texas	14

Clinical Trial Progress for COMBIVIR

Clinical Trial Phase

Clinical Trial Phase for COMBIVIR
Clinical Trial Phase	Trials
Phase 4	21
Phase 3	16
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for COMBIVIR
Clinical Trial Phase	Trials
Completed	52
Unknown status	4
Suspended	2

Clinical Trial Sponsors for COMBIVIR

Sponsor Name

Sponsor Name for COMBIVIR
Sponsor	Trials
National Institute of Allergy and Infectious Diseases (NIAID)	12
Glaxo Wellcome	10
GlaxoSmithKline	8

Sponsor Type

Sponsor Type for COMBIVIR
Sponsor	Trials
Industry	50
Other	36
NIH	22

Combivir (lamivudine + zidovudine) Clinical Trials Update, Market Analysis, and Exclusivity/Generic Outlook

Last updated: July 28, 2026

Combivir, a fixed-dose combination of lamivudine (3TC) + zidovudine (AZT), is an established antiretroviral therapy for HIV-1. There is no credible basis for a current “clinical trials update” or near-term regulatory-driven growth catalyst because Combivir is an off-patent, legacy product with HIV treatment strategies dominated by newer regimens (including single-tablet and integrase-based therapies).

What does the latest clinical evidence say for Combivir in HIV-1, and which trials still matter?

Direct, product-specific late-stage trials for Combivir are not a relevant near-term driver in 2024-2026 HIV R&D portfolios. Modern trials largely test new drug classes, new combinations, and regimen-simplification strategies rather than fixed-dose AZT/3TC legacy backbones.

Which indications does Combivir still support clinically?

Combivir is used for HIV-1 infection as part of combination antiretroviral therapy. The practical relevance today is mainly in settings where:

• formularies prioritize older generic backbones,
• regimen selection is constrained by cost,
• clinicians manage specific tolerability or availability needs.

What endpoints would define modern “clinical trials update” relevance?

Even when studies reference AZT/3TC backbones, the decision metrics are typically:

• virologic suppression rate (HIV RNA below assay thresholds),
• resistance outcomes (especially M184V for lamivudine and thymidine-analogue resistance patterns for zidovudine),
• regimen tolerability and discontinuation rates,
• time-to-treatment-failure.

How big is the Combivir market today, and what segments drive revenue?

Combivir is a legacy HIV product with a mature, low-growth commercial profile in markets where it is still stocked. Revenue today is driven by:

• continued prescribing in resource-constrained settings,
• low-cost generic availability (which compresses pricing),
• residual demand under national HIV formularies.

Commercial demand split: developed vs. emerging markets

• Developed markets: Combivir use is limited versus newer regimens. Prescriber migration to integrase inhibitor-based therapy structurally reduces demand.
• Emerging markets: generic antiretroviral procurement and national guidance may sustain usage of older NRTI backbones in some programs, but market expansion is constrained by global treatment guideline shifts.

Pricing and margin reality check

For legacy combination products with widespread generic substitution, market performance is typically characterized by:

• rapid price erosion,
• tender-driven volume swings,
• limited brand premium versus multi-source generics.

When does Combivir lose exclusivity and how does that affect generic substitution risk?

Combivir is not in an active exclusivity window in major markets in the mid-2020s. Its commercial and litigation landscape is therefore dominated by:

• generic substitution dynamics,
• any residual intellectual property that may relate to specific formulations, packaging, or manufacturing processes (if claimed in certain jurisdictions).

What is the practical exclusivity status?

In practice, Combivir has long been available as generics. As a result:

• competitive risk comes from generic market share capture, not “entry-blocking” exclusivity.
• brand-level forecasting depends on tender execution rather than patent protection.

What patent estate is relevant for Combivir (lamivudine + zidovudine), and what generic entry barriers remain?

Combivir’s relevant IP estate historically covers:

• compound-level patents for lamivudine and zidovudine (expired in most major jurisdictions),
• combination and formulation patents (if any were granted and remained in force in specific countries),
• manufacturing/process patents (potentially narrower and jurisdiction-dependent).

Actionable outcome for business planning: there is no plausible expectation of new exclusivity leverage for Combivir as a classically legacy NRTI fixed-dose combination.

What is the FDA/Orange Book status of Combivir, and what does it imply for ANDA entry timing?

Combivir is an FDA-approved drug product with multiple generic alternatives available historically through ANDA pathways. The commercial implication:

• any “timing” question is no longer about first-to-market approvals but about ongoing supply and pricing under generic competition.

Regulatory pathway implication for future entrants

For a legacy two-NRTI fixed-dose combination, the main constraints are:

• bioequivalence proof,
• manufacturing controls,
• ongoing labeling requirements rather than exclusivity timing.

How does Combivir compare with today’s standard-of-care HIV regimens, and what does that mean for market trajectory?

Standard-of-care HIV regimens have structurally moved away from zidovudine + lamivudine backbones. Modern practice emphasizes:

• integrase inhibitor-based regimens,
• high barrier to resistance and simplified dosing,
• better tolerability profiles (reducing AZT-related hematologic toxicity risks).

Competitive displacement mechanics

Combivir demand declines due to:

• guideline preference shifts,
• resistance interpretation leading clinicians to avoid older backbones where possible,
• safety/tolerability tradeoffs versus modern NRTI-sparing and INSTI-based strategies.

Where are clinical trials likely to still mention Combivir, and what would “update” look like?

The only realistic “update” channels for a legacy combination are:

• retrospective cohort analyses using historical backbone data,
• real-world evidence comparing regimen durability where older backbones were used during earlier guideline periods,
• pharmacovigilance and safety surveillance for AZT-related adverse events in specific subpopulations.

Those are monitoring and evidence-generation activities, not product-defining late-stage registrational programs.

What market projections should you use for Combivir, and what are the key drivers of downside/upside?

Base-case market projection: flat-to-declining unit volumes with continued price erosion in most competitive markets.
Upside scenarios are mainly procurement-driven:

• inclusion in specific national formularies due to cost,
• supply reliability and tender wins for low-cost manufacturers,
• niche clinical persistence where modern regimens are constrained.

Downside scenarios dominate:

• continued guideline shift away from AZT/3TC,
• substitution by lower-cost multi-tablet or alternative FDCs with better tolerability,
• tender specification tightening to newer backbones.

KPI framework for forecasting Combivir sales

Use a tender-and-formulary model rather than a brand uptake model:

• number and size of public health tenders specifying AZT/3TC,
• contract award share by supplier,
• average realized price per tablet (net of rebates where applicable),
• availability of competing generic FDCs (and competitor lead times),
• country guideline updates.

What litigation or settlements affect Combivir generics?

Given Combivir’s legacy status and broad generic availability, litigation risk is typically:

• sporadic jurisdiction-specific disputes,
• not a major driver of national supply.

A litigation-driven forecast should be anchored to whether any active case affects a specific jurisdiction’s supply chain. For business planning, this usually translates into monitoring:

• court dockets where generic challengers dispute Orange Book-listed patents,
• any consent decrees or settlement agreements that alter launch timing.

Key Takeaways

• Combivir is a legacy HIV fixed-dose combination with limited near-term clinical trial relevance and no growth catalyst consistent with modern HIV standards.
• Commercial performance is governed by generic price competition and tender/formulary dynamics, not brand differentiation.
• Exclusivity timing is not a meaningful planning lever; the market is shaped by generic substitution and guideline displacement.
• Business forecasts should use a procurement-led model with country guideline tracking, not an R&D-led uptake curve.

FAQs

1. Why do integrase inhibitor-based regimens reduce demand for zidovudine/lamivudine backbones?
2. What resistance patterns matter most when using lamivudine-containing regimens in treatment-experienced patients?
3. How do public health procurement tender specifications typically affect legacy antiretroviral combination sales?
4. What safety events drive clinician switching away from zidovudine-containing regimens?
5. How should a manufacturer structure supply capacity for multi-source competition in legacy HIV FDCs like Combivir?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Combivir listings and related products). U.S. Food and Drug Administration.
2. U.S. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. HIV.gov.
3. WHO. Consolidated guidelines for HIV prevention, testing, treatment, service delivery and monitoring. World Health Organization.